Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gylden Chikungunya vaccine
- Development stage
- Preclinical
- Lead developer
- Gylden Pharma
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Intramuscular
01
Overview
The Gylden Chikungunya vaccine is a preclinical-stage synthetic T cell-priming vaccine being developed by Gylden Pharma for the prevention of Chikungunya virus (CHIKV) infection. Utilizing a proprietary synthetic platform, the vaccine is designed to elicit a robust and specific T-cell mediated immune response, rather than relying solely on the induction of neutralizing antibodies. This approach aims to provide broad and durable protection against the virus by targeting conserved viral epitopes. As of early 2024, the vaccine remains in the preclinical phase of development.
- Other names
- Gylden Pharma Chikungunya vaccineSynthetic T cell-priming Chikungunya vaccine
02
Targets
MHC I (MHC class I})Chikungunya virus-specific CD8+ T cell receptor
Beyond the preview
Go deeper on Gylden Chikungunya vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gylden Chikungunya vaccine.